BioMelbourne Network
Progressing BioIndustry
News and Opinions
2011
November
CogState signs $2.6m sales contract
CogState Ltd (ASX:CGS) today announced that it has signed a contract with an international pharmaceutical company to participate in a phase 2 clinical trial for the treatment of Major Depressive Disorder.
Under the contract, which will generate US$2.6 million of revenue for CogState over the study duration, CogState will provide its cognitive testing technology and associated services to 60... read more…
HealthLinx CEO to retire in 2012
Mr Nick Gatsios will resign as CEO of HealthLinx Limited (ASX: HTX). Mr Gatsios was a founding director of the private company when it was established in 2002 and has been CEO of the company since it listed on the ASX in 2006.
In a decision reached by both parties, Mr Gatsios will extend his contracted notice period by two months to remain with the company as managing director until 30 June 2... read more…
AusIndustry releases R&D Tax Discussion Paper
An objective of the Australian Government is to transition the R&D Tax Incentive into a significant vehicle for driving the nation’s innovation system through increased research and development.
AusIndustry’s aim is to engage with a wide range of audiences to encourage an innovation culture and enable the development of strong guidance material for the R&D Tax Incentive. We are seeking partici... read more…
Mesoblast posts successful results from diabetes stem cell trial
Revascor™ Mesoblast’s proprietary Mesenchymal Precursor Cell (MPC) product for cardiovascular diseases, was safe and well-tolerated at all doses, with no clinically relevant immune responses to donor cells.
Revascor™therapy significantly reduced cardiac mortality and major adverse cardiac events (MACE) in patients with congestive heart failure over a mean follow-up of ... read more…
Phosphagenics raises $3 million in oversubscribed SPP
Victoria-based Phospagenics (ASX:POH) has raised $3 million in a heavily oversubscribed share purchasing plan to fund the development of its targeted drug delivery products.
The Victorian biotech will put the proceeds towards its activities commercialising drug delivery applications using its Targeted Penetration Matrix (TPM) technology.
The capital raising follows a $24.1 million placeme... read more…
Cancer scientist awarded prestigious 2011 Victoria Prize
Victorian Minister for Innovation, Services and Small Business Louise Asher announced at a ceremony in Parliament House that Professor Andreas Strasser has won Victoria’s highest honour for science in 2011, the prestigious $50,000 Victoria Prize, for his groundbreaking work in cancer.
Ms Asher said that Professor Strasser’s research had provided extraordinary insight into how cells work and wh... read more…
Prostate Collaboration to Continue with Garvan Institute
13 November 2011HealthLinx Limited (ASX:HTX) and the Garvan Institute of Medical Research have agreed to continue their research collaboration to include a larger patient cohort following positive results from the initial study into prostate cancer. The aim of the study was to assess the expression of proprietary HealthLinx biomarker/s in plasma samples provided by the Garvan Institute a... read more…
Victoria’s $150 million technology commitment
11 November, 2011 - The Victorian Coalition Government has committed $150 million to secure Victoria’scompetitive edge and maintain the state’s reputation as Australia’s technology hub.Technology Minister Gordon Rich-Phillips said the investment would advance Victoria’sappeal for local, national and international ICT businesses.“New technologies are central to the Victorian Coalition Government... read more…
Broadvector completes acquisition of CSIRO’s intellectual property for its prostate cancer therapy and related vaccine technology
10 November 2011 | Melbourne Australia Broadvector Limited (‘Broadvector’) has successfully completed the acquisition of intellectual property rights from the CSIRO, which underpin a potential treatment for early stage prostate cancer and a related vaccine technology. As a part of the terms of the intellectual property acquisition transaction CSIRO has become a major shareholder in Broadvecto... read more…
Immuron Submits Investigational New Drug Application for Fatty Liver Disease and NASH with US FDA
8 November 2011Immuron Limited (ASX: IMC) has submitted an application for an Investigational New Drug (IND) for its proprietary IMM-124E fatty liver disease product candidate with the US Food and Drug Administration (FDA). This follows an encouraging pre-IND meeting with the FDA earlier this year.IMM-124E is a potential new treatment of fatty liver disease, in particular Non-Alcoholic Ste... read more…
